Molecular Prospective on Malignant Transformation of Mesenchymal Stem Cells: An Issue in Cell Therapy.


Journal

Cellular reprogramming
ISSN: 2152-4998
Titre abrégé: Cell Reprogram
Pays: United States
ID NLM: 101528176

Informations de publication

Date de publication:
Jun 2024
Historique:
medline: 25 6 2024
pubmed: 25 6 2024
entrez: 25 6 2024
Statut: ppublish

Résumé

Mesenchymal stem cell (MSCs) therapy, as a rapidly developing area of medicine, holds great promise for the treatment of a variety of medical conditions. MSCs are multipotent stem cells that can be isolated from various tissues and could self-renew and differentiate. They secrete cytokines and trophic factors that create a regenerative microenvironment and have immunomodulatory properties. Although clinical trials have been conducted with MSCs in various diseases, concerns regarding the possibility of malignant transformation of these cells have been raised. The studies showed a higher rate of hematological malignancy and carcinogenesis in experimental models after MSC transplantation. The mechanisms underlying malignant transformation of MSCs are complex and not fully understood, but they are believed to involve the presence of special signaling molecules and alterations in cell behavior regulation pathways. Possible pathways that lead to MSCs' oncogenic transformation occur through two mechanisms: spontaneous and stimulated malignant transformation, including cell fusion, fusion proteins, and the tumor microenvironment. MSC-based therapies have the potential to revolutionize medicine, and addressing the issue of malignancy is crucial to ensure their safety and efficacy. Therefore, the purpose of the present review is to summarize the potential mechanisms of the malignant transformation of MSCs. [Figure: see text].

Identifiants

pubmed: 38917438
doi: 10.1089/cell.2024.0026
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

96-106

Auteurs

Maryam Kaviani (M)

Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Saeede Soleimanian (S)

Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Allergy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Somayeh Keshtkar (S)

Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Molecular Dermatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Negar Azarpira (N)

Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Zahra Asvar (Z)

Nanotechnology School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran.

Sara Pakbaz (S)

Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Department of Laboratory Medicine & Pathobiology, Mount Sinai Hospital, Toronto, ON, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH